Systems Biology: A Disruptive Technology

By Ken Rubenstein, PhD

FIGURES

Figure 1.1. Causation in Living Systems Is a Two-Way Street
Figure 1.2. Experimentally Accessible Levels of Systems Biology
Figure 2.1. The BG Medicine Approach to Commercial Systems Biology
Figure 2.2. Graphic Representation of a BG Medicine Correlation Network Using Proteomic and Metabolomic Data
Figure 2.3. Multicomponent Protein and Metabolite Biomarkers for Distinguishing Among Normal Controls, Alzheimer’s Disease, and Mild Cognitive Impairment
Figure 2.4. ChIP-on-Chip Workflow
Figure 2.5. Cytoscape Graphical User Interface
Figure 2.6. Ariadne Genomics’ Pathway Studio Graphical User Interface
Figure 2.7. Tumor Angiogenesis Network Generated by the Ingenuity Pathways Analysis System
Figure 2.8. Genstruct’s Forward and Reverse Causal Analysis Schema
Figure 3.1. Modeling of Biological Systems at Multiple Levels
Figure 3.2. Important Cellular Networks
Figure 3.3. Human Disease Network/Disease Gene Network
Figure 5.1. Respondents by Sector
Figure 5.2. Respondents by Position
Figure 5.3. Respondents by Stage of Work
Figure 5.4. Use of Systems Biology in R&D Projects
Figure 5.5. Areas of Systems Biology Involvement
Figure 5.6. Companies’ Views Toward Systems Biology
Figure 5.7. Means by Which Systems Biology Effort Is Conducted
Figure 5.8. Vendor Emphasis in Outsourced Systems Biology Efforts
Figure 5.9. Expectations for Fiscal 2008 Systems Biology Budget
Figure 5.10. Expectations for Systems Biology Budget over the Next 3 Years
Figure 5.11. Estimation of 2008 Systems Biology Budget

TABLES

Table 1.1. Growth in Literature Citations Relevant to Systems Biology During the Period 1998 to 2007
Table 5.1. Business Models of Small Systems Biology Companies
Table 5.2. Selected Recent Deals in the Systems Biology Space